Pipeline
Our lead product, MelCancerVac® has been tested in clinical trials for the treatment of two different types of cancer, colorectal cancer (CRC) and non-small-cell lung cancer (NSCLC).
CRC Clinical Trials
- Phase II at Gentofte Hospital, Denmark *Completed
- Phase II at the National Cancer Centre, Singapore *Completed
- Phase IIb at the National Cancer Centre, Singapore Starts Q3 2008
NSCLC Clinical Trials
- Phase II at Herlev Hospital, Denmark *Ongoing
Therapeutic Pipeline
Legend to figure:
Left hand arrow shows current state of development and the right hand part of the arrow shows future product development plans. The original MCV has been replaced by improved MCV.
- CRC – colorectal cancer
- NSCLC – non small cell lung cancer
- OPC – oesophageal cancer
- MCV – MelCancer Vac
- MCVi – improved Mel Cancer Vac, replaces MCV from 2006/7
- MCV5AZA – Melanoma cell line is stimulated with 5-azacytidine to improve antigen expression
- NCV – New Cancer Vac to complement MCV, perhaps 2 or 3 new lysates
- CCV – Combined Cancer Vac, new vaccine including all lysate strains
- Combo – combination of MCV with other cancer therapies